[Comparative clinical study of the effectiveness of the new anti-arrhythmia agents, trimecaine and pyrromecaine].

Abstract

The antiarrythmic effects of trimecain and pyromecain were studied in 53 patients with frequent ventricular premature beats. Trimecain was given to 22 patients and pyromecain was given to 31. The efficiency of both intravenous and oral drug administration was considered. Comparative drugs--lidocain, mexityl, procainamid were parallely used. The efficiency criterion was the decrease in mean ventricular premature beats per hour by 50% or more during ECG-monitoring. A positive antiarrhythmic effect of intravenous trimecain was observed in 35.3% of the patients, that of pyromecain was in 18.2% and after administration of a related compound lidocain, it was seen in 30.0% and 26.7%, respectively. Trimecain in tablets proved to be efficacious in 15.4% of the patients in a single dose and in 18.2% after its long-term therapy, while mexityl, a comparative agent was efficacious in 63.6%. Pyromecain in tablets did not lead to decrease in ectopia either during an "acute" test or during the long-term therapy whereas procainamid was effective in 37.3% of the patients studied.